This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 6.42% and 73.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
by Zacks Equity Research
Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
by Zacks Equity Research
Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
by Zacks Equity Research
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
by Zacks Equity Research
Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.05% and 74.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants
by Zacks Equity Research
A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -13.95% and 65.14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: BBIO, ARGX Soar on Study Results, APLS Down on Safety Issues
by Zacks Equity Research
Regulatory and key pipeline updates from BridgeBio (BBIO) and argenx (ARGX) are in focus in the biotech sector.
Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio
by Zacks Equity Research
Alnylam's (ALNY) revenues continue to be driven by Amvuttra and Givlaari sales. Its existing collaboration agreement with Regeneron to develop RNAi-based candidates is progressing well.
BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study
by Zacks Equity Research
BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.
Company News for Jul 18, 2023
by Zacks Equity Research
Companies In The News Are: F, TSLA, BBIO, PARA.
BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?
by Zacks Equity Research
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -9.52% and 74.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 1.61% and 8.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last?
by Zacks Equity Research
BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why
by Zacks Equity Research
Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism.
Is BridgeBio Pharma (BBIO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how BridgeBio Pharma (BBIO) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.
Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More
by Zacks Equity Research
Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.